10-K: Passage Bio 10-K Filing: Strategic Shift and Focus on Neurodegenerative Diseases

Passage Bio's 10-K filing highlights a strategic shift towards neurodegenerative diseases, prioritizing PBFT02 development and exploring out-licensing opportunities for pediatric programs.

Summary

• Passage Bio is a clinical-stage genetic medicines company focused on developing treatments for neurodegenerative diseases.
• The company's lead candidate, PBFT02, is being developed for frontotemporal dementia (FTD) caused by progranulin deficiency (FTD-GRN).
• PBFT02 utilizes an AAV1 capsid to deliver a functional granulin gene to the brain via intra cisterna magna (ICM) administration.
• Initial clinical data from the upliFT-D trial showed supraphysiologic levels of CSF PGRN in patients treated with PBFT02.
• The company plans to explore PBFT02 in additional neurodegenerative diseases, including FTD-C9orf72, ALS, and Alzheimer's disease (AD).
• Passage Bio is pursuing out-licensing opportunities for its pediatric programs in GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy.
• The company has a research collaboration with the University of Pennsylvania's Gene Therapy Program (GTP) for discovery and preclinical development.
• As of December 31, 2023, Passage Bio had $114.3 million in cash, cash equivalents, and marketable securities, expected to fund operations into the fourth quarter of 2025.
• The company reported a net loss of $102.1 million for the year ended December 31, 2023.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there are positive aspects such as promising initial clinical data and a strategic focus on neurodegenerative diseases, there are also significant risks and challenges, including financial losses, reliance on a single clinical candidate, and competition. The company's strategic shift and focus on PBFT02 are positive, but the need for additional funding and the uncertainty of clinical development temper the overall outlook.

Positives

• Initial clinical data for PBFT02 in FTD-GRN shows promising biomarker results with supraphysiologic CSF PGRN levels.
• The company is expanding the application of PBFT02 to multiple neurodegenerative indications, potentially diversifying revenue streams.
• Passage Bio has a strong research collaboration with GTP, providing access to advanced gene therapy technologies.
• The company has established robust in-house analytical and process development operations.
• The company has secured cGMP manufacturing capacity with Catalent to support clinical trials and potential commercial launch.

Negatives

• The company has a history of operating losses and expects to continue incurring losses for the foreseeable future.
• PBFT02 is currently the sole clinical-stage product candidate, creating a reliance on its success.
• The company has paused enrollment in the Imagine-1 trial for PBGM01 and is pursuing out-licensing opportunities.
• The company has stopped further clinical development of PBKR03 and PBML04, also pursuing out-licensing.
• The company is dependent on third-party manufacturers for clinical supply of its product candidates.
• The company faces significant competition in the genetic medicines field.
• The company has limited experience designing and implementing clinical trials and has never conducted pivotal clinical trials.

Risks

• The company may not achieve or sustain profitability and will need to raise additional funding.
• The development and commercialization of PBFT02 may not be successful.
• Preclinical and clinical development is a lengthy and expensive process with an uncertain outcome.
• Gene therapy is a novel technology, making it difficult to predict the time and cost of product development and regulatory approval.
• Product candidates may cause undesirable side effects, delaying or preventing advancement or approval.
• The company relies on its collaboration with Penn for preclinical research and development.
• The company faces significant competition and may not be successful in marketing its product candidates.
• The company may experience manufacturing problems that result in delays or harm to its business.
• The company may be subject to unfavorable pricing regulations or third-party coverage and reimbursement policies.
• The company may be unable to obtain and maintain patent protection or other necessary rights for its products and technology.

Future Outlook

The company expects its existing cash, cash equivalents, and marketable securities will enable it to fund operating expenses and capital expenditure requirements into the fourth quarter of 2025. The company plans to continue clinical development of PBFT02, explore its potential in additional neurodegenerative indications, and pursue out-licensing opportunities for pediatric programs.

Management Comments

• The company believes it has developed a differentiated approach to developing treatments for central nervous system disorders.
• The company believes that genetic medicines have the potential to significantly change the course of neurodegenerative diseases.
• The company is prioritizing the execution of the ongoing upliFT-D study, with the goal of advancing this program to the registrational phase.
• The company believes that its differentiated approach of advancing one genetic medicine candidate to treat multiple indications is a cost-effective strategy.

Industry Context

The document highlights the competitive landscape in the biotechnology and pharmaceutical industries, particularly in the genetic medicines field. It mentions several companies developing gene therapies for FTD-GRN, including Alector, Prevail Therapeutics, and AviadoBio, indicating a growing interest and competition in this area. The document also notes the presence of other companies using different therapeutic approaches, such as small molecules and recombinant proteins, to target FTD-GRN, further emphasizing the competitive nature of the market.

Comparison to Industry Standards

• The document mentions several competitors in the FTD-GRN space, including Alector, Prevail Therapeutics, AviadoBio, Kyowa Kirin, QurAlis Therapeutics, Denali Therapeutics, Takeda Pharmaceutical Company Limited, and VesperBio.
• Alector is conducting a Phase 3 clinical trial with a humanized anti-human sortilin monoclonal antibody for FTD-GRN, indicating a more advanced stage of development compared to Passage Bio's Phase 1/2 trial.
• Prevail Therapeutics (now part of Eli Lilly & Co) is conducting a Phase 1/2 clinical trial for a gene therapy treatment for FTD-GRN, similar to Passage Bio's approach.
• AviadoBio began enrolling their Phase 1/2 gene therapy trial in patients with FTD-GRN in the second half of 2023, suggesting a similar timeline to Passage Bio's program.
• Denali Therapeutics in partnership with Takeda Pharmaceutical Company Limited is conducting a Phase 1/2 clinical trial for their recombinant progranulin protein, a different approach than Passage Bio's gene therapy.
• VesperBio began Phase 1 enrollment for a small molecule sortilin antagonist program targeting FTD-GRN in the fourth quarter of 2023, representing a different therapeutic modality.
• The document highlights that Passage Bio's approach of using AAV1 capsid and ICM administration for PBFT02 led to extensive and robust expression of human PGRN throughout the brain and spinal cord of non-human primates, and due to the higher PGRN levels in cerebral spinal fluid, or CSF, achieved using AAV1 as compared with other serotypes tested, which is a key differentiator compared to other gene therapy approaches.

Management Changes

Legal Proceedings

• The company is a defendant in litigation with a former employee relating to a claim of breach of contract and violation of the Pennsylvania Wage Payment and Collection Law.
• The plaintiff claims that, pursuant to an alleged settlement agreement reached on February 3, 2020, the company agreed to issue plaintiff 150,000 shares of its common stock and that such shares would not be subject to the reverse stock split implemented by the company in connection with its initial public offering on February 14, 2020.
• The plaintiffs claim is for an amount in the mid-single digit millions of dollars.
• The company disagrees with the allegations and believes the plaintiffs claim is without merit.
• The Court denied both the Companys and the plaintiffs motions for summary judgement and therefore the company anticipates that this matter will go to trial in 2024.

Stakeholder Impact

• Shareholders face risks related to potential dilution, market volatility, and the uncertainty of product development.
• Employees may experience job insecurity due to restructuring and workforce reductions.
• Patients with neurodegenerative diseases may benefit from the development of new treatments, but face uncertainty regarding the success and availability of these therapies.
• Suppliers and creditors may be affected by the company's financial performance and ability to meet its obligations.
• Customers may be impacted by the pricing and availability of the company's products, if approved.

Next Steps

• Initiate dosing of Cohort 2 FTD-GRN patients in the upliFT-D trial in the first half of 2024.
• Report six-month safety and biomarker data from Cohort 1 patients in the second half of 2024.
• Report 12-month follow-up data from Cohort 1 patients and initial safety and biomarker data from Cohort 2 patients in the first half of 2025.
• Obtain regulatory feedback on the clinical pathway to treating FTD-C9orf72 and ALS patients with PBFT02 in the second half of 2024.
• Initiate preclinical studies in AD to extend initial observations.

Key Dates

Keywords

gene therapy, neurodegenerative diseases, progranulin, PBFT02, FTD-GRN, clinical trials, AAV, manufacturing, out-licensing, biotechnology